伊伐布雷定心率控制对脓毒症患者血流动力学影响:前瞻性多中心随机对照试验研究方案
本研究为前瞻性、多中心、随机、开放标签试验,计划纳入172例第三代脓毒症与脓毒性休克定义标准、血流动力学优化后窦性心率仍≥95次/分的脓毒症患者,随机分为标准治疗组或伊伐布雷定组(标准治疗+肠内伊伐布雷定,维持心率70-94次/分),主要结局为随机后96小时内两组心率降至95次/分以下的差异及伊伐布雷定对血流动力学的影响。
要点
- 脓毒症持续心动过速与高死亡率相关,适当控制心率可能改善预后。
- 伊伐布雷定通过抑制If电流直接降低心率,无负性肌力作用。
- 主要结局为随机后96小时内两组心率降至95次/分以下的差异及伊伐布雷定对血流动力学的影响。
核心结论
- 研究旨在评估直接窦房结抑制能否改善脓毒症患者血流动力学及其对器官功能和预后的影响,为临床安全使用提供证据。
研究设计与样本
- 前瞻性、多中心、随机、开放标签研究,计划纳入172例脓毒症患者。
- 纳入标准为第三代脓毒症与脓毒性休克定义标准、血流动力学优化后窦性心率≥95次/分的脓毒症患者。
- 患者随机分为标准治疗组(GS)或伊伐布雷定组(GI,标准治疗+肠内伊伐布雷定)。
主要发现
- GI组接受伊伐布雷定维持心率在70-94次/分。
- 主要结局为随机后96小时内两组心率降至95次/分以下的差异及伊伐布雷定对血流动力学的影响。
- 次要结局包括器官功能指标、SOFA评分差异、不良事件发生率、器官支持需求、ICU住院时间和28天总死亡率。
关键数值与推荐
- GI组伊伐布雷定维持心率目标为70-94次/分。
- 主要结局评估时间窗为随机后96小时内。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Sepsis, a life-threatening syndrome, is often accompanied by tachycardia in spite of hypovolemia and hypotension have been corrected. Recently, relevant studies have shown that sustained tachycardia in sepsis was related to high mortality, and appropriate control of heart rate (HR) could improve prognosis. Ivabradine reduces HR directly without a negative inotropic effect through inhibition of the If ionic current, which is different from the traditional rate control drug (beta-blockers). METHODS AND ANALYSIS: This is a prospective, multicenter, randomized, open label study designed to investigate the effect of heart rate control with ivabradine on hemodynamic in patients with sepsis. Our study will enroll 172 patients with sepsis as defined by The Third International Consensus Definitions for Sepsis and Septic Shock criteria with sinus rate of 95 bpm or higher despite a hemodynamic optimization. Patients will be randomly assigned to standard treatment group (GS) or ivabradine group (GI, standard treatment for sepsis plus enteral ivabradine). Patients in GI will receive ivabradine to maintain HR between 70 and 94 bpm. The primary outcome is the difference of a reduction in HR below 95 bpm and the effect of ivabradine on hemodynamics between GI and GS group within the first 96 h after randomization. The secondary outcomes include organ function measures, the difference in SOFA score, incidence of adverse events, need for organ support, length of ICU stay, and 28-day overall mortality. DISCUSSION: There are limited studies on ivabradine to control heart rate in patients with sepsis. Our study aims to evaluate whether direct sinus node inhibition can improve hemodynamics, as well as its impact on organ function and prognosis in patients with sepsis, so as to provide evidence for the safe usage in clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov NCT05882708. Registered on May 11, 2023, https://clinicaltrials.gov/ct2/show/NCT05882708 .
引用
- Zheng J, Wen D, Pan Z, et al. Effect of heart rate control with ivabradine on hemodynamic in patients with sepsis: study protocol for a prospective, multicenter, randomized controlled trial. Trials. 2024. PMID: 39443954. doi:10.1186/s13063-024-08560-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。